
|Articles|January 22, 2007
ASCO GI: Transplant Shows Best Survival for Local Liver Cancer Therapy
ORLANDO -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma -- but these patients make up a heterogeneous group.
Advertisement
ORLANDO, Jan. 22 -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma.
So said Roderich Schwarz, M.D., of the Cancer Institute of New Jersey in New Brunswick, who compared survival for three local treatment strategies -- transplant, surgical resection, and ablation.
After five years, the survival rate for transplant patients was 67%, versus 38% for those who had surgical resection and 19% for ablation procedures (P
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Pre-Vaccine Antibodies May Predict Blunted COVID-19 Vaccine Response
2
Once-Weekly Insulin Icodec Strengthens the Case for CGM Use in Primary Care
3
FDA Clears First-of-Its-Kind Alzheimer Blood Test for Adults With Cognitive Symptoms
4
FDA Authorizes First Wearable Device to Continuously Monitor Glucose, Ketones
5
























































































































